NIH R01 · 2025
Studying the role of eIF4A in Pancreatic Cancer
PROJECT SUMMARY Pancreatic ductal adenocarcinoma (PDA) remains largely incurable and recent studies have shown that the metabolic pathways of PDA cells are profoundly rewired. Nonetheless, this metabolic rewiring may also engender liabilities that can be exploited for PDA treatment. Using genetically-engineered mouse models and pancreatic ductal organoids, we previously showed that PDA cells are dependent upon KRAS-mediated increases in protein synthesis. As several key oncogenic signaling pathways converge on the eukaryotic translation initiation factor 4F (eIF4F), we recently examined whether an inhibitor (CR-31) of its associated RNA helicase (eIF4A) affects the viability of PDA cells.…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.